Clinical trial
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage…
NCT00089193 · Craig L Slingluff, Jr, Other · Completed
Key facts
| NCT number | NCT00089193 |
|---|---|
| Title | Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma |
| Official title | Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides |
| Lead sponsor | Craig L Slingluff, Jr, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim |
| Start date | Sep 1, 2003 |
| Primary completion | Feb 1, 2007 |
| First posted | Aug 5, 2004 |
| Last update posted | Dec 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: